<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>PHYSOSTIGMINE SALICYLATE- physostigmine salicylate injection </strong><br>Cardinal Health<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>Physostigmine Salicylate Injection </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ea6092f9-dcfb-4216-b6a7-3c72e14cd553"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_c72afdc1-1f05-4eda-bf7d-83f0e790ac27"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION: </h1>
<p class="First">Physostigmine Salicylate Injection is a derivative of the Calabar bean, and its active moiety, physostigmine, is also known as eserine. Its chemical structure is: </p>
<div class="Figure">
<a name="id202"></a><img alt="chemical structure " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b81350a6-715b-451c-87e9-3674ec29ffd8&amp;name=image-01.jpg">
</div>
<p>It is soluble in water and a 0.5% aqueous solution has a pH of 5.8. </p>
<p>Physostigmine Salicylate Injection is available in 2 mL ampules, each mL containing 1 mg of Physostigmine Salicylate in a vehicle composed of sodium metabisulfite 0.1%, benzyl alcohol 2.0% as a preservative in Water for Injection. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_633699ca-d956-40b6-84d1-141c0bedfe9a"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY: </h1>
<p class="First">Physostigmine Salicylate Injection is a reversible anticholinesterase which effectively increases the concentration of acetylcholine at the sites of cholinergic transmission. The action of acetylcholine is normally very transient because of its hydrolysis by the enzyme, acetylcholinesterase. Physostigmine Salicylate Injection inhibits the destructive action of acetylcholinesterase and thereby prolongs and exaggerates the effect of the acetylcholine. </p>
<p>Physostigmine Salicylate Injection contains a tertiary amine and easily penetrates the blood brain barrier, while an anticholinesterase, such as neostigmine, which has a quaternary ammonium ion is not capable of crossing the barrier. Physostigmine Salicylate Injection can reverse both central and peripheral anticholinergia. The anticholinergic syndrome has both central and peripheral signs and symptoms. Central toxic effects include <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> may produce <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, medullary <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Peripheral toxicity is characterized by <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, vasodilation, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, diminution of gastrointestinal motility, decrease of secretion in salivary and sweat glands, and loss of secretions in the pharynx, bronchi, and nasal passages. </p>
<p>Dramatic reversal of the effects of anticholinergic symptoms can be expected in minutes after the intravenous administration of Physostigmine Salicylate Injection, if the diagnosis is correct and the patient has not suffered <span class="product-label-link" type="condition" conceptid="313601" conceptname="Oxygen supply absent">anoxia</span> or other insult. The duration of action of Physostigmine Salicylate Injection is relatively short, approximately 45 to 60 minutes. </p>
<p>Numerous drugs and some plants produce the anticholinergic syndrome either directly or as a side effect; this undesirable or potentially dangerous phenomenon may be brought about by either therapeutic doses or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of the drugs. Such drugs include among others, atropine, other derivatives of the belladonna alkaloids, tricyclic antidepressants, phenothiazines, and antihistamines. </p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_ba83932f-c388-49c4-8355-9cc11f89fbb7"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE: </h1>
<p class="First">To reverse the effect upon the central nervous system, caused by clinical or toxic dosages of drugs capable of producing the anticholinergic syndrome. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_7f1b3fb9-9e4c-4150-8b42-6c10cc262e6e"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS: </h1>
<p class="First">Physostigmine Salicylate Injection should not be used in the presence of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, cardiovascular disease, mechanical obstruction of the intestine or urogenital tract or any vagotonic state, and in patients receiving choline esters and depolarizing neuromuscular blocking agents (decamethonium, succinylcholine). </p>
<p>For post-anesthesia, the concomitant use of atropine with physostigmine salicylate is not recommended, since the atropine antagonizes the action of physostigmine. </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_aa199beb-da6e-4453-8cb9-96a8ad0fefe9"></a><a name="section-6"></a><p></p>
<h1>WARNINGS: </h1>
<p class="First">Contains sodium bisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in non-<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> people. </p>
<p>If excessive symptoms of <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, urination and defecation occur, the use of Physostigmine Salicylate Injection should be terminated. If excessive <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> occur, the dosage should be reduced. </p>
<p>Intravenous administration should be at a slow, controlled rate, no more than 1 mg per minute (see <a href="#i4i_dosage_admin_id_7d4180e2-4c19-42d9-860c-ca8ff2736c55">dosage</a>). Rapid administration can cause <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">hypersalivation</span> leading to a respiratory difficulties and possible <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. </p>
<p>An overdosage of Physostigmine Salicylate Injection can cause a <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span>. </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_8ab99e8d-20c1-452a-b8ee-952a50a3543a"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS: </h1>
<p class="First">Because of the possibility of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> in an occasional patient, atropine sulfate injection should always be at hand since it is an antagonist and antidote for physostigmine. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_b6cf931b-89f1-43c3-b5a1-56aeb8625190"></a><a name="section-8"></a><p></p>
<h1>USAGE IN PREGNANCY: </h1>
<p class="First">Safe use in pregnancy and lactation has not been established; therefore, use in pregnant women, nursing mothers or women who may become pregnant requires that possible benefits be weighed against possible hazards to mother and child. </p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_c3739e0a-a8e7-4ac9-af37-250e106fba5b"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS: </h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>; can be offset by reducing dosage. <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, if intravenous administration is too rapid. See <a href="#i4i_dosage_admin_id_7d4180e2-4c19-42d9-860c-ca8ff2736c55">DOSAGE AND ADMINISTRATION</a>. </p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_1aaacd3c-ccf5-4e1f-aa69-df955dcc306e"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE: </h1>
<p class="First">Can cause a <span class="product-label-link" type="condition" conceptid="4311957" conceptname="Cholinergic crisis">cholinergic crisis</span>. Appropriate antidote is atropine sulfate. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_7d4180e2-4c19-42d9-860c-ca8ff2736c55"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION: </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ef0e11c0-e913-42d6-a499-2a326e1f8fc6"></a><a name="section-11.1"></a><p></p>
<p class="First"><span class="Bold">Past Anesthesia Care:</span> 0.5 to 1.0 mg intramuscularly or intravenously. INTRAVENOUS ADMINISTRATION SHOULD BE AT A SLOW CONTROLLED RATE OF NO MORE THAN 1 MG PER MINUTE. Dosage may be repeated at intervals of 10 to 30 minutes if desired patient response is not obtained. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_52010d6a-ac16-4e83-b889-44d045228974"></a><a name="section-12"></a><p></p>
<h1>OVERDOSAGE OF DRUGS THAT CAUSE ANTICHOLINERGIC: </h1>
<p class="First">2.0 mg intramuscularly or INTRAVENOUSLY AT SLOW CONTROLLED RATE (SEE ABOVE). Dosage may be repeated if life threatening signs, such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> occurs. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6fdd19f4-4420-48ae-8175-62b3b0da1454"></a><a name="section-13"></a><p></p>
<h1>PEDIATRIC DOSAGE: </h1>
<p class="First">Recommended dosage is 0.02 mg/kg; intramuscularly or by slow intravenous injection, no more than 0.5 mg per minute. If the toxic effects persist, and there is no sign of cholinergic effects, the dosage may be repeated at 5 to 10 minute intervals until a therapeutic effect is obtained or a maximum of 2 mg dosage is attained. </p>
<p>IN ALL CASES OF <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">POISONING</span>, THE USUAL SUPPORTIVE MEASURES SHOULD BE UNDERTAKEN. </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_08279570-f143-4954-a441-ae6c2ccd0e4c"></a><a name="section-14"></a><p></p>
<h1>HOW SUPPLIED: </h1>
<p class="First">NDC 17478-510-02<br>2 mL Ampules packed 10 per box, 1 mg per mL. </p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_815262cc-5dba-44cb-bb7e-b2ea020c03d7"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">STORAGE:</span> Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. </p>
<p>SOME DRUGS WHICH PRODUCE THE ANTICHOLINERGIC SYNDROME </p>
<p>Amitriptyline, Amoxapine, Anisotropine, Atropine, Benztropine, Biperiden, Carbinoxamine, Clidinium, Cyclobenzaprine, Desipramine, Doxepin, Homatropine, Hyoscine, Hyoscyamine, Hyoscyamus, Imipramine, Lorazepam, Maprotiline, Mepenzolate, Nortriptyline, Propantheline, Protriptyline, Scopolamine, Trimipramine. </p>
<p>SOME PLANTS THAT PRODUCE THE ANTICHOLINERGIC SYNDROME </p>
<p>Black Henbane, Deadly Night Shade, Devil's Apple, Jimson Weed, Loco Seeds or Weeds, Matrimony Vine, Night Blooming Jessamine, Stinkweed. </p>
<p><span class="Bold">Akorn</span><br>Manufactured by: Akorn, Inc.<br>Lake Forest, IL 60045 </p>
<p>PS00N<br>Rev. 11/08 </p>
<p>Cardinal Health</p>
<p>Zanesville, OH 43701</p>
<p>IA67220113</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_8369d810-03a3-4ddb-ae78-a7fa6ce4ea66"></a><a name="section-15"></a><p></p>
<h1>Principal Display Panel</h1>
<p class="First">Physostigmine Salicylate</p>
<p>Injection (1 mg/mL)</p>
<p>1 x 2 mL Ampule</p>
<div class="Figure">
<a name="id-605430116"></a><img alt="bag label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b81350a6-715b-451c-87e9-3674ec29ffd8&amp;name=image-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PHYSOSTIGMINE SALICYLATE 		
					</strong><br><span class="contentTableReg">physostigmine salicylate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-1281(NDC:17478-510)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>physostigmine salicylate</strong> (physostigmine) </td>
<td class="formItem">physostigmine salicylate</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium metabisulfite</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>benzyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-1281-8</td>
<td class="formItem">1  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 AMPULE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">08/10/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-1281)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e653b80b-f8fa-4169-a5cb-427b4599a59e</div>
<div>Set id: b81350a6-715b-451c-87e9-3674ec29ffd8</div>
<div>Version: 2</div>
<div>Effective Time: 20141027</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
